
Bioventus BVS
$ 7.61
-0.52%
Quarterly report 2025-Q3
added 11-04-2025
Bioventus Accounts Receivables 2011-2026 | BVS
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Bioventus
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123 M | 136 M | 125 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 136 M | 123 M | 128 M |
Quarterly Accounts Receivables Bioventus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 130 M | 132 M | 118 M | 122 M | 137 M | 126 M | 113 M | 120 M | 119 M | 136 M | 132 M | 143 M | 119 M | 125 M | 105 M | 102 M | 89.5 M | 88.3 M | 88.3 M | 88.3 M | 88.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 143 M | 88.3 M | 115 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 22.36 | 17.07 % | $ 241 M | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 40.61 | 1.35 % | $ 1.13 B | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
DarioHealth Corp.
DRIO
|
3.16 M | $ 12.13 | -10.01 % | $ 344 M | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 28.01 | 7.77 % | $ 847 M | ||
|
BioNano Genomics
BNGO
|
4.75 M | $ 1.6 | -0.62 % | $ 2.03 M | ||
|
Co-Diagnostics
CODX
|
304 K | $ 6.03 | 5.79 % | $ 177 M | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Danaher Corporation
DHR
|
3.54 B | $ 235.57 | -0.44 % | $ 172 B | ||
|
DexCom
DXCM
|
974 M | $ 70.1 | 0.3 % | $ 27.1 B | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
249 M | $ 101.63 | -0.02 % | $ 18.8 B | ||
|
Mettler-Toledo International
MTD
|
687 M | $ 1 470.87 | -0.96 % | $ 31.2 B | ||
|
Myriad Genetics
MYGN
|
121 M | $ 6.63 | 1.69 % | $ 601 M | ||
|
CareDx, Inc
CDNA
|
51.1 M | $ 18.9 | 0.48 % | $ 1.02 B | ||
|
National Research Corporation
NRC
|
12.4 M | $ 18.9 | -2.07 % | $ 464 M | ||
|
Natera
NTRA
|
244 M | $ 254.4 | 2.28 % | $ 25 B | ||
|
Anixa Biosciences
ANIX
|
173 K | $ 3.28 | 3.14 % | $ 105 K | ||
|
OPKO Health
OPK
|
118 M | $ 1.36 | 3.03 % | $ 944 M | ||
|
Precipio
PRPO
|
1.3 M | $ 23.27 | 1.26 % | $ 30.2 M | ||
|
Guardant Health
GH
|
110 M | $ 109.93 | -2.14 % | $ 13.5 B | ||
|
Personalis
PSNL
|
8.14 M | $ 9.35 | 2.19 % | $ 554 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
3.2 B | $ 244.29 | 1.58 % | $ 44.3 B | ||
|
Illumina
ILMN
|
735 M | $ 150.14 | 2.01 % | $ 23.9 B | ||
|
Charles River Laboratories International
CRL
|
721 M | $ 216.77 | 0.31 % | $ 11.1 B | ||
|
Thermo Fisher Scientific
TMO
|
8.19 B | $ 617.15 | -0.58 % | $ 236 B | ||
|
Twist Bioscience Corporation
TWST
|
57 M | $ 36.55 | -0.87 % | $ 2.19 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 178.14 | -1.27 % | $ 19.8 B | ||
|
Biodesix
BDSX
|
8.6 M | $ 5.96 | -1.16 % | $ 773 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 253.73 | -2.56 % | $ 21.3 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 202.92 | 0.71 % | $ 16.7 B | ||
|
IDEXX Laboratories
IDXX
|
474 M | $ 714.55 | 1.09 % | $ 58.9 B |